Your browser doesn't support javascript.
loading
Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies.
Jiang, Shuwen; Li, Xiangkun; Xue, Weifang; Xia, Sumei; Wang, Jian; Sai, Yang; Dai, Guangxiu; Su, Weiguo.
Affiliation
  • Jiang S; HUTCHMED Limited, Zhangjiang Hi-Tech Park, Shanghai, China.
  • Li X; HUTCHMED Limited, Zhangjiang Hi-Tech Park, Shanghai, China.
  • Xue W; HUTCHMED Limited, Zhangjiang Hi-Tech Park, Shanghai, China.
  • Xia S; HUTCHMED Limited, Zhangjiang Hi-Tech Park, Shanghai, China.
  • Wang J; HUTCHMED Limited, Zhangjiang Hi-Tech Park, Shanghai, China.
  • Sai Y; HUTCHMED Limited, Zhangjiang Hi-Tech Park, Shanghai, China.
  • Dai G; HUTCHMED Limited, Zhangjiang Hi-Tech Park, Shanghai, China.
  • Su W; HUTCHMED Limited, Zhangjiang Hi-Tech Park, Shanghai, China.
Front Pharmacol ; 15: 1392209, 2024.
Article in En | MEDLINE | ID: mdl-38948472
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Pharmacol Year: 2024 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Pharmacol Year: 2024 Document type: Article